Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium-lactobacillus triple live bacteria
- Development stage
- Unknown
- Lead developer
- Shuangqi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium-Lactobacillus triple live bacteria is a probiotic pharmaceutical product primarily marketed in China under the brand name Golden Bifid (Jinshuangqi). It is a live biotherapeutic product (LBP) formulation that typically consists of three bacterial strains: *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. The drug is designed to restore the natural balance of intestinal flora, inhibit the proliferation of pathogenic microorganisms, and strengthen the intestinal mucosal barrier. It is clinically approved for the treatment of intestinal dysbiosis and associated symptoms such as diarrhea, constipation, and abdominal distension. Recent clinical research, including Phase 4 trials conducted at institutions like West China Hospital, is evaluating its efficacy in treating small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), and as an adjunctive therapy for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease.
- Brand names
- Golden BifidJinshuangqi
- Other names
- Bifidobacterium-Lactobacillus Triple Live BacteriaBifidobacterium and Lactobacillus Triple Live BacteriaBifidobacterium, Lactobacillus and Enterococcus Triple Live Bacteria双歧杆菌乳杆菌三联活菌
Beyond the preview
Go deeper on bifidobacterium-lactobacillus triple live bacteria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium-lactobacillus triple live bacteria.